Heart in Diabetes conference to spotlight cutting-edge clinical cardiometabolic science
Click Here to Manage Email Alerts
Key takeaways:
- The Heart in Diabetes conference will host its eighth annual meeting June 7-9 in Philadelphia.
- The meeting will feature new recommendations from the Diabetes, CardioRenal and Metabolic Diseases Task Force.
Multidisciplinary experts from across cardiometabolic subspecialties will gather again to showcase the latest clinical research at the Heart in Diabetes CME Conference.
The annual conference, now in its eighth year, brings together world-renowned clinical leaders in diabetes, CVD and beyond, according to Yehuda Handelsman, MD, FACP, FNLA, FASCP, MACE, medical director and principal investigator of the Metabolic Institute of America in Tarzana, California, and co-chair of Heart in Diabetes. The program is designed to evaluate the state-of-the-art clinical data and research while focusing on the management of the heart and kidneys in diabetes.
Handelsman said the main goal of the conference is to align cardiologists, endocrinologists, diabetologists, hepatologists, nephrologists and all other interested clinicians in their clinical management plans for very high-risk patients.
“There is no other meeting that puts together such a multidisciplinary group in the cardiorenal metabolic space,” Handelsman told Healio. “It is a meeting where you will find all the top faculty in their respective fields, all in one place. You see many of them at larger meetings like the American Diabetes Association, the American College of Cardiology or the Endocrine Society, but never in one small intimate place together. This meeting is unique in that respect. The meeting also includes state-of-the-art clinical science, including unpublished data, which you do not find often.”
The conference will take place June 7 to 9 at the Hilton Philadelphia at Penn’s Landing hotel. The 3-day conference will be a live, in-person conference followed by 90 days of access to all meeting materials on demand. The conference will offer 27 CME/maintenance of certification (MOC) credits.
Highlights of this year’s conference include the following:
- On Friday, the Hypercortisolism Implication to Cardiorenal and Metabolic Disease session will include presentations on the impact of hypercortisolism on hypertension, hyperglycemia and beyond with Ralph A. DeFronzo, MD, and the medical treatment of hypercortisolism with relacorilant with Rosario Pivonello, MD, PhD.
- A session on Women’ Health, beginning Saturday morning, will feature presentations on MI and CV death in young women in the U.S. and the consequences of functional hypothalamic amenorrhea with Chrisandra L. Shufelt, MD, MS.
- A joint symposium with the journal Circulation will include presentations on optimal HF screening among adults with diabetes without atherosclerotic CVD with Ambarish Pandey, MD, the treatment and prevention of diabetic foot ulcers in the CV patient population with Katherine A. Gallagher, MD, and the estimated lifetime benefits of SGLT2 inhibitors, GLP-1 receptor agonists and mineralocorticoid receptor antagonists in people with type 2 diabetes and albuminuria with Muthiah Vaduganathan, MD, MPH.
- The 2024 Luminary in Cardiometabolic Medicine Award will be presented Saturday to Mikhail Kosiborod, MD, FACC, FAHA, followed by a lecture, titled “The rise of cardiometabolic medicine: How metabolic agents transformed cardiovascular care.”
- George Grunberger, MD, will chair an abstract oral presentation session with cheese and wine on Saturday evening, showcasing abstracts published in the American Heart Journal. The oral abstract awards presentation will take place on Sunday.
On Friday, Healio | Endocrine Today Co-Editor Richard Pratley, MD, and Healio | Cardiology Today Editorial Board Member Javed Butler, MD, will chair a session on multispecialty practice recommendations for diabetes, cardiorenal and metabolic diseases from the Diabetes, CardioRenal and Metabolic Diseases Task Force (DCRM). As Healio previously reported, the recommendations developed by the DCRM Task Force covered 18 interrelated cardiometabolic disorders and are designed for use by both primary care physicians and specialists. Handelsman, also a co-author of the guidelines, said the “DCRM 2.0” will spotlight previously underappreciated conditions, such as prediabetes, obesity, inflammation and pulmonary conditions.
“The patient is not in a silo; the patient has many medical conditions,” Handelsman told Healio. “We all used to work one disease, one drug, one specialty. Our patients have HF, kidney disease, high BP, lipids, sometimes diabetes, obesity. They are not just covered by an endocrinologist or a nephrologist. How do we get around that? We put together a document recognizing that medical societies typically create guidelines from the viewpoint of their own specialty. Here, we took people from the different specialties and said can we produce recommendations that the endocrinologist, the nephrologist, the cardiologist and the PCP will all agree on for this complicated patient?”
The DCRM 2.0 consensus document will be simultaneously published in Metabolism and available free for download, Handelsman said.
“This is not a conference rehashing old data; it is not taking a lecture off the shelf,” Handelsman told Healio. “Every speaker has a lecture they had to prepare for this meeting. It is clinical, and it has implications for clinical practice.”
The Healio team will provide live coverage from Heart in Diabetes, including reports on the sessions and debates, video interviews and more, which can be seen at Healio.com/HeartinDiabetes. For more information on the conference, visit https://www.heartindiabetes.com/.
For more information:
Program and registration information is available at heartindiabetes.com/registration.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts